Non Hodgkin Lymphoma Clinical Trial
PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)
Summary
Brief Summary:
This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1160 in participants with solid tumors.
Participants will have solid tumor or liquid cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
This study will have two parts. Part A of the study will find out how much and how frequently PRO1160 should be given to participants. Part B will use the dose and schedule found in Part A to find out how safe PRO1160 is and if it works to treat the diseases under study.
Renal Cell Carcinoma (RCC) Drug: PRO1160 Phase 1/Phase 2 Nasopharyngeal Carcinoma (NPC) Non-Hodgkin Lymphoma (NHL)
Full Description
This is a Phase 1/2 study of PRO1160, a CD70 targeted antibody-drug conjugate, to evaluate the safety, tolerability, PK, and antitumor activity of PRO1160 in patients with selected locally advanced /or metastatic solid and liquid tumors, including renal cell carcinoma, nasopharyngeal carcinoma and non-hodgkin lymphoma. This study consists of 2 parts, Part A: Dose Escalation and Part B: Dose Expansion.
Part A may evaluate up to 7 dose levels of PRO1160 on Day 1 of a 21 day cycle by IV infusion.
Part B will be initiated at a dose level based on a comprehensive analysis of safety, tolerability, clinical PK, PD and activity data from Part A in up to 4 different cohorts of up to 20 patients per cohort.
Patients will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.
Eligibility Criteria
Inclusion Criteria:
Pathologically confirmed metastatic or unresectable solid malignancy including Renal Cell carcinoma, Nasopharyngeal carcinoma or Stage III or IV Non Hodgkin Lymphoma
Relapsed or refractory disease following prior systemic therapies known to confer medical benefit
Willing to provide a tumor sample (archive tissue or fresh biopsy)
ECOG performance status 0 or 1
Measurable disease per RECIST v1.1 for RCC and NPC and per Lugano for NHL
Exclusion Criteria:
Prior treatment with anti-CD70 directed therapy
Other malignancy within 3 years
Active CNS metastases (treated, stable CNS metastases are allowed)
Uncontrolled Grade 3 or greater infection within 2 weeks
Positive for HBV, HCV or HIV
Use of a strong P450 CYP3A inhibitor within 14 days (dose escalation only)
Additional protocol defined inclusion/exclusion criteria may apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 14 Locations for this study
Duarte California, 91010, United States
Irvine California, 92618, United States
Ann Arbor Michigan, 48109, United States
Detroit Michigan, 48201, United States
Saint Louis Missouri, 63110, United States
Bronx New York, 10467, United States
New York New York, 10016, United States
Charlotte North Carolina, 28204, United States
Cleveland Ohio, 44195, United States
Portland Oregon, 97213, United States
Portland Oregon, 97239, United States
Nashville Tennessee, 37203, United States
Houston Texas, 77030, United States
West Valley City Utah, 84119, United States
Beijing Beijing, , China
Shanghai Shanghai, , China
Shanghai Shanghai, , China
How clear is this clinincal trial information?